A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs ASP 7713 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Astellas Pharma BV
- 27 Jul 2017 Planned number of patients changed from 128 to 148.
- 27 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 27 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.